Primary Care Physician Referral Practices Regarding BRCA1/2 Genetic Counseling in a Major Health System
Overview
Authors
Affiliations
Purpose: The United States Preventive Services Task Force recommends primary care physicians refer patients at high risk for BRCA1/2 mutations to genetic testing when appropriate. The objective of our study was to describe referrals for BRCA1/2 testing in a large integrated health system and to assess factors associated with referral.
Methods: This retrospective cohort study includes female patients between 18 and 50 years who had a primary care visit in the Cleveland Clinic Health System between 2010 and 2019. We used multivariable logistic regression to estimate differences in the odds of a woman being referred for BRCA1/2 testing by patient factors and referring physician specialty. We also assessed variation in referrals by physicians.
Results: Among 279,568 women, 5% were high risk. Of those, 22% were referred for testing. Black patients were significantly less likely to be referred than white patients (aOR 0.87; 95% CI 0.77, 0.98) and Jewish patients were more likely to be referred than non-Jewish patients (aOR 2.13; 95% CI 1.68, 2.70). Patients primarily managed by OB/GYN were significantly more likely to be referred than those cared for via Internal/Family Medicine (aOR 1.45; 95% CI 1.30, 1.61). Less than a quarter of primary care physicians ever referred a patient for testing.
Conclusion: The majority of primary care patients at high risk for a BRCA1/2 mutation were not referred for testing, and over a decade, most physicians never referred a single patient. Internal/Family Medicine physicians, in particular, need support in identifying and referring women who could benefit from testing.
Behery M, Bahbah A, Mohamed Shawqi M, El-Said Y, Sherif L, Ataallah H BMC Cancer. 2025; 25(1):237.
PMID: 39934731 PMC: 11817763. DOI: 10.1186/s12885-025-13530-4.
Genetics and Primary Care: Raising Awareness and Enhancing Cooperation.
Tuc Bengur E, Heeley J Mo Med. 2024; 121(4):277-283.
PMID: 39575065 PMC: 11578565.
Russell C, Daley A, Van Arnem D, Hila A, Johnson K, Davies J Hered Cancer Clin Pract. 2024; 22(1):24.
PMID: 39516903 PMC: 11545665. DOI: 10.1186/s13053-024-00298-0.
Commentary: Why is genetic testing underutilized worldwide? The case for hereditary breast cancer.
Pederson H, Narod S BJC Rep. 2024; 2(1):73.
PMID: 39516714 PMC: 11523979. DOI: 10.1038/s44276-024-00099-x.
Abdel-Razeq H, Sharaf B, Tamimi F, Bani Hani H, Alsmadi O, Khalil H Front Oncol. 2024; 14:1431985.
PMID: 39507757 PMC: 11537866. DOI: 10.3389/fonc.2024.1431985.